MedTrace Logo

DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE

NCT00900536 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to sorafenib.

PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.

Conditions

Interventions

GENETIC

mutation analysis

GENETIC

polymorphism analysis

GENETIC

protein expression analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

Principal Investigators

  • Timothy Eisen · Cancer Research UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2012-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900536 on ClinicalTrials.gov